The aim of this article was to present a review of the research literature on the outcome of botulinum toxin type A (BTX-A) injection for management of upper limb spasticity in children with cerebral palsy (CP). We searched the electronic databases of MEDLINE, CINAHL and PUBMED for all published studies with full-length English text available. For each study, the quality of the methods and the ...

The aim of this study was to compare the effect of neuro-development treatment (NDT) technique and NDT plus botulinum toxin type A (BTX-A) injection on the reduction of spasticity and improvement of the quality of movement patterns of lower limb in hemiplegic patients. For this purpose, 15 hemiplegic (8 female and 7 male cases) with an age range of 27-70 years participated in this study. The pa...

The aim of this study was to compare the effect of neuro-development treatment (NDT) technique and NDT plus botulinum toxin type A (BTX-A) injection on the reduction of spasticity and improvement of the quality of movement patterns of lower limb in hemiplegic patients. For this purpose, 15 hemiplegic (8 female and 7 male cases) with an age range of 27-70 years participated in this study. The pa...

Botulinum neurotoxin type-A (BoNT-A) has been used in association with other interventions in the management of spasticity in children with cerebral palsy (CP) for almost two decades. This consensus statement is based on an extensive review of the literature by an invited international committee. The use of BoNT-A in the lower limbs of children with spasticity caused by CP is reported using the...

OBJECTIVE We aimed to develop a goal classification of individualised goals for spasticity treatment incorporating botulinum toxin intervention for upper limb spasticity to under-pin a more structured approach to future goal setting. DESIGN Individualised goals for spasticity treatment incorporating botulinum toxin intervention for upper limb spasticity (n=696) were analysed initially from fo...

The clinical eVects of botulinum toxin have been recognised since the end of the 19th century. It is the most potent neurotoxin known and it is produced by the gram negative anaerobic bacterium Clostridium botulinum. The paralytic eVect of the toxin is due to blockade of neuromuscular transmission. Injection into a muscle causes chemodenervation and local paralysis and this eVect has led to the...